ATE493985T1 - Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden - Google Patents

Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Info

Publication number
ATE493985T1
ATE493985T1 AT03736611T AT03736611T ATE493985T1 AT E493985 T1 ATE493985 T1 AT E493985T1 AT 03736611 T AT03736611 T AT 03736611T AT 03736611 T AT03736611 T AT 03736611T AT E493985 T1 ATE493985 T1 AT E493985T1
Authority
AT
Austria
Prior art keywords
treatment
ischemia
reperfusion injury
beta blocker
pyrroloquinoline quinones
Prior art date
Application number
AT03736611T
Other languages
English (en)
Inventor
Paul J Davis
Original Assignee
Clf Medical Technology Acceleration Program Inc
Paul J Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clf Medical Technology Acceleration Program Inc, Paul J Davis filed Critical Clf Medical Technology Acceleration Program Inc
Application granted granted Critical
Publication of ATE493985T1 publication Critical patent/ATE493985T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03736611T 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden ATE493985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/146,566 US7276514B2 (en) 2002-05-15 2002-05-15 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
PCT/US2003/015187 WO2003097056A1 (en) 2002-05-15 2003-05-14 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE493985T1 true ATE493985T1 (de) 2011-01-15

Family

ID=29418840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736611T ATE493985T1 (de) 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Country Status (8)

Country Link
US (2) US7276514B2 (de)
EP (1) EP1558256B1 (de)
JP (1) JP2005530786A (de)
AT (1) ATE493985T1 (de)
AU (1) AU2003237851A1 (de)
CA (1) CA2497601A1 (de)
DE (1) DE60335647D1 (de)
WO (1) WO2003097056A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7276514B2 (en) 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
JP2007536256A (ja) * 2004-05-05 2007-12-13 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
US9458465B2 (en) * 2007-12-04 2016-10-04 Rutgers, The State University Of New Jersey Compositions and methods to modulate cell membrane resealing
EP2062892A4 (de) * 2006-09-08 2009-11-18 Kyowa Hakko Bio Co Ltd Mittel gegen hypertonie
JP5672751B2 (ja) * 2010-04-07 2015-02-18 三菱瓦斯化学株式会社 ピロロキノリンキノンを含むリポソーム
WO2011142744A1 (en) * 2010-05-11 2011-11-17 University Of Medicine And Dentistry Of New Jersey Compositions and methods for the treatment and prevention of cardiac ischemic injury
EP2635908B1 (de) 2010-11-05 2015-08-19 University of Medicine and Dentistry of New Jersey Serum mg53 als diagnostischer marker für gewebeverletzungen
CN103533936B (zh) * 2011-05-17 2016-01-13 三菱瓦斯化学株式会社 含有吡咯并喹啉醌和糖的脂质体
CN103619842B (zh) 2011-06-16 2016-06-22 三菱瓦斯化学株式会社 吡咯并喹啉醌二钠盐的结晶及其制造方法
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN108026091B (zh) * 2015-09-25 2021-02-09 浙江海正药业股份有限公司 吡咯并喹啉醌钠盐的晶型及其制备方法和用途
US20190298684A1 (en) * 2018-03-27 2019-10-03 So Young Life Sciences Corporation Compositions For Reducing Negative Effects Of Alcohol Consumption
CN110870866A (zh) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用
IT202000025603A1 (it) * 2020-10-28 2022-04-28 Longeva Health S R L Composizione per prevenire e trattare lo scompenso e/o l’insufficienza cardiaca

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1302275C (en) * 1986-08-07 1992-06-02 Yuji Narutomi Enzyme inhibitor
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5145862A (en) * 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
EP0603301B1 (de) * 1991-09-09 1998-01-14 Warner-Lambert Company Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
WO1993010784A1 (en) 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
US5460819A (en) * 1991-12-13 1995-10-24 Children's Medical Center Corporation Method for treating PQQ-responsive heavy metal toxicity
US5616576A (en) * 1994-07-12 1997-04-01 The Children's Medical Center Corporation Controlling bone resorption with pyrroloquinoline quinone (PQQ) and related compounds
WO1998043621A1 (en) 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
WO2004010924A2 (en) * 2002-04-04 2004-02-05 Children's Medical Center Corporation Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof

Also Published As

Publication number Publication date
AU2003237851A1 (en) 2003-12-02
EP1558256A1 (de) 2005-08-03
JP2005530786A (ja) 2005-10-13
US20080221145A1 (en) 2008-09-11
CA2497601A1 (en) 2003-11-27
DE60335647D1 (de) 2011-02-17
WO2003097056A1 (en) 2003-11-27
EP1558256B1 (de) 2011-01-05
US20030216424A1 (en) 2003-11-20
US7276514B2 (en) 2007-10-02

Similar Documents

Publication Publication Date Title
ATE493985T1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
HUP0401590A2 (hu) Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
ATE419859T1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE499098T1 (de) Verwendung von parp-1-hemmern
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
DK1483366T3 (da) Antimikrobiel sammensætning
GB0111186D0 (en) Novel compounds
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ZA202304093B (en) Neuregulin-4 compounds and methods of use
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases
DE60335093D1 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
WO2006015183A3 (en) Pharmaceutical compositions for treating disorders of the skin
ATE454897T1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties